BACKGROUND
In the last decades enormous efforts have been made to develop therapeutic interventions that boost antitumor immunity, including adoptive cell transfer, anticancer vaccination, application of oncolytic viruses, and immune checkpoint inhibition (8, 9) . A wide range of immunotherapeutic strategies are being tested in glioblastoma, advanced by successes in other tumor types. In these approaches particularly T cells are targeted as final effector cells by, for example, dendritic cell vaccination or immune checkpoint inhibition, but durable responses remain limited to case reports (10) . Boosted T cell responses as a result of, for example, vaccination strategies encounter functional impairment due to immune inhibitory mechanisms both in the tumor microenvironment and systemically. To overcome T cell inhibition hope was pinned on immune checkpoint inhibition with monoclonal antibody therapy against PD1 and CTLA-4. Nevertheless, to date clinical trials testing immune
This is an open access article under the terms of the Creative Commons AttributionNonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Cytometry Part A 95A: 422-426, 2019 OMIP checkpoint inhibition in glioblastoma have not shown impressive results (11) . Clearly glioblastoma-specific immune suppression is a complex and unsolved problem that remains an obstacle for successful immunotherapies. Therefore, a better understanding of glioblastoma immune escape and contributing factors is warranted, alongside the development of biomarkers for patient selection and prediction of clinical response. Immune suppression in glioblastoma is largely mediated by infiltration of monocytes into the glioblastoma microenvironment (12) . Myeloid immune cells dominate immune infiltrates and are involved in glioblastoma disease progression (13) (14) (15) . Although some subsets have been studied in isolation, the different types of infiltrating myeloid and lymphoid cells, their recruitment from the bone marrow and spleen, and their phenotypic distribution need further investigation.
Mass cytometry provides for the simultaneous measurement of more than 40 parameters at single cell resolution, improving the ability of cytometry to characterize the complexity of the immune system (16) . Similar to the development of antibody panels for multichromatic fluorescence cytometry, mass cytometry panel development requires optimization of antibody-metal pairing, conjugation of antibodies with metal polymers, determination of optimal antibody concentrations, and optimization of buffers and staining conditions. Here we developed a mass cytometry immunophenotyping panel, which was designed to quantify population frequencies and to infer functional states of T cells, including activation, differentiation, exhaustion, or anergy in the murine glioblastoma microenvironment ( Fig. 1) and spleen. Furthermore, our panel helps to differentiate and quantify a multitude of glioblastoma infiltrating and bone marrow derived myeloid cell subsets and immune cells resident to the bone marrow. Although this panel is optimized for single cell suspensions obtained from mouse brain, spleen, and bone marrow it could also be applied to the study of innate and adaptive components of the immune system in other mouse organs. Single cell suspensions were generated using mechanical dissociation and enzymatic digestion using the Neural Tissue Dissociation kit P (Miltenyi, Germany) (17) . After live/dead staining and barcoding (1) cells were cryopreserved until antibody staining and mass cytometry analysis (Fig. 1A) . Following data pre-processing including bead normalization (18) hi recently extravasated monocytes (population 8), and some clusters of macrophages with different phenotypes and/or states of activation (9A, 9B, 9C, 9D, 9E, and 9F) based on their expression of CCR2, MHC-II, PD-L1, CD38, and CD88. Gated populations were identified based on two-dimensional embeddings of the high dimensional space visualized using the viSNE algorithm in Cytobank (Fig. 1B,C) .
Enzymatic digestions often result in the cleavage of molecules on the membrane of immune cells, which could have detrimental effect in their recognition by antibodies. In order to allow direct comparison amongst different organs (brain, spleen, and bone marrow) all samples were subjected to the same enzymatic treatment as it was required for the processing of the brain samples. The panel presented in this OMIP has been optimized to the single cell suspension preparation procedure as suggested by the manufacturer with some minor adjustments (see Supporting Information "Online Protocol"). Care should be taken to specifically address any effects of alterations in the tissue dissociation protocol to the performance of this panel.
SIMILARITY TO OTHER OMIPS
This OMIP is partly overlapping with OMIP-032, which describes two murine multicolor immunofluorescence panels including the following markers to detect B and T lymphocytes, natural killer cells, dendritic cells, macrophages, monocytes, and neutrophils: CD45, TCRβ, CD4, CD8, Ly6C, CD49b, Ly6G, CD11c, MHCII, CD206, NKp46, CD62L, and CD44 (19) . These markers overlap with our panel except for CD49b, NKp46, and CD62L. Since our panel is more focused on activation and exhaustion in T lymphocytes, we included more antibodies against activation markers and co-inhibitory molecules (immune checkpoints) rather than the presence of naïve or memory T cells. Also OMIP-031 has overlap with a panel aimed at immune checkpoint expression (20) , which reports the following markers: CD3, CD4, CD8, CD69, CD44, CD45RA, CD27, CD62L, KLRG127, CD127, PD-1, CTLA4, TIM-3, LAG-3, and CD45. Our panel includes all of these markers except for CD45RA, CD27, CD62L, KLG127, and LAG-3. Previously, three other mass cytometry panels have been published. They focus on the characterization of human peripheral leukocytes (OMIP-34), human head and neck (21) (22) (23) . This is the first mass cytometry OMIP for a comprehensive characterization of the mouse immune system. All data used generated during the optimization and verification of this panel can be found in FlowRepository under ID: FR-FCM-ZYUF. 
